The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

INTRODUCTION

Proteolytic enzymes influence a diverse spectrum of biologic processes integral to tumor growth and metastasis. Many features of cancer invasion parallel complex attributes of organogenesis that require orchestrated protease-mediated interactions with the extracellular environment. Although early studies of protease activity in tumorigenesis focused on activities directed toward local structural barriers directly restraining tumor expansion, subsequent work has determined roles for proteases in all phases of tumor progression through mechanisms that involve the liberation and activation of growth factors, direct proinvasive signaling through cell-surface receptors, and the modification of distant metastatic site microenvironments.

Of the more than 170 human serine proteases identified to date, members of the small subfamily of type II transmembrane serine proteases (TTSP) are of particular interest due to compartmentalized expression patterns localizing activity to a limited number of cell types, and demonstrated roles as direct contributors to cancer progression (1–3). TTSPs comprise a group of modular proteins that contain an N-terminal cytoplasmic domain of 20 to 60 amino acids, a transmembrane domain, and a variable array of domains that invariably comprise a protease catalytic triad (4). The most extensively studied member of the TTSP family, matriptase/MT-SP1/ST14, is overexpressed in several tumors of epithelial origin, including carcinoma of the ovary, uterus, prostate, colon, cervix, and skin (reviewed in ref. 5), and is associated with poor outcomes in many studies of these malignancies. Hepsin/TMPRSS1 has been consistently shown to be overexpressed in prostate cancers at levels up to 30-fold above benign epithelium (6, 7). Overexpression of hepsin in murine prostate epithelium results in a disrupted basement membrane, leading to weakened adhesion between epithelium and stroma. High levels of hepsin expression in the context of neoplastic transformation endow prostate tumor cells with the ability to complete the full metastatic process (8).

Transmembrane serine protease 2 (TMPRSS2) is a TTSP expressed in prostate epithelium and is upregulated in aggressive prostate cancers (9). TMPRSS2 is normally expressed several fold higher in the prostate relative to any other human tissue, although the normal physiologic function remains unknown. Importantly, unlike other TTSPs, TMPRSS2 transcription is regulated by androgenic ligands and the androgen receptor (AR; ref. 10). This feature has been hypothesized to contribute to the high frequency of genomic rearrangements involving the TMPRSS2 promoter and members of the ETS gene family, particularly ERG, which places this oncogene under AR control (11, 12). Other than the contribution of TMPRSS2 regulatory sequences to these genomic rearrangements, the role of TMPRSS2 in neoplasia has not been established.

In this study, we investigated the influence of TMPRSS2 on prostate carcinoma. We established that TMPRSS2 is consistently expressed at high levels in metastatic prostate
cancers and is regulated by androgenic hormones in vivo. By developing mouse models with genetically altered TMPRSS2 activity in the prostate, we determined that TMPRSS2 promotes metastasis. Using high-throughput screens of combinatorial peptide libraries, we identified pro-hepatocyte growth factor (HGF) as a TMPRSS2 substrate and confirmed that HGF and its cognate receptor c-MET are activated in prostate cancers expressing TMPRSS2, a finding that also associated with the acquisition of a pro-invasive mesenchymal gene expression program. By screening small-molecule libraries, we identified a bioavailable inhibitor of TMPRSS2 that suppressed prostate cancer metastasis. Together, these findings provide a mechanistic link between androgen-regulated signaling and prostate cancer metastasis that operates via interactions with components of the tumor microenvironment.

RESULTS
The TMPRSS2 Protease Is Highly Expressed in Metastatic Prostate Cancers and Is Regulated by Androgenic Hormones In Vivo

The TTSP family members hepsin and matriptase directly influence the invasive and metastatic capabilities of cancers arising in the prostate and other organs. Previous studies determined that these proteases, and the TTSP TMPRSS2, are elevated in localized prostate cancers (6, 9, 13). To directly compare the relative abundance of these highly similar proteases, we microdissected neoplastic epithelium from localized (n = 14) and metastatic (n = 40) prostate cancers and quantitated transcript levels in cancer foci. We found that TMPRSS2 levels exceeded those of both TMPRSS1 and ST14 in the majority of prostate cancers evaluated (P < 0.01 for all comparisons; Fig. 1A and B). In accord with transcript levels, TMPRSS2 protein is elevated in primary cancers relative to benign epithelium (Fig. 1B), and localized to the luminal surface of benign polarized secretory epithelial cells, a location that excludes contact with basement membrane or stromal cells. In contrast, loss of basal epithelium in prostate cancer allowed TMPRSS2-expressing invasive neoplastic cells to directly interact with structural and cellular constituents of prostatic stroma (Fig. 1B).

The presence of high TMPRSS2 levels in invasive prostate cancers prompted further investigation of TMPRSS2 in metastasis (Fig. 1C). Patients with advanced prostate cancer disseminate tumor cells to multiple distant sites, although predominantly to lymph node and bone. To assess the frequency and consistency of TMPRSS2 expression in metastatic cancer tissue, we procured tumor tissue from at least three distinct foci from 44 men with metastatic disease. The vast majority (132 of 166) of metastasis to soft tissues and bone expressed high levels of the TMPRSS2 protein, and different metastasis from the same individual all generally exhibited concordant high (common) or low (rare) TMPRSS2 staining (Fig. 1D). Those few tumors with absent or very low TMPRSS2 expression were notable for low or absent AR expression. Although rearrangements involving TMPRSS2 and ERG are usually accompanied by loss of one TMPRSS2 allele, we found no significant differences in TMPRSS2 expression between tumors with high or low ERG expression (Fig. 1E and F). The consistent retention of high levels of TMPRSS2 in prostate cancer metastasis suggested that this protease may exert a functional role in tumor cell dissemination and survival in foreign sites.

TMPPRSS2 Expression Is Regulated by Androgens In Vivo

The cellular signaling program regulated by the AR is a primary target of prostate cancer therapies, although the critical AR-regulated effector components responsible for the genesis or progression of prostate cancer have not been defined. In vitro experiments determined that TMPRSS2 expression is promoted through AR and potentially via estrogen receptor regulation (10, 14, 15). In support of these observations, we found a positive correlation between AR and TMPRSS2 in microdissected primary tumor epithelium (r² = 0.39; P < 0.001). This positive correlation was also evident in metastatic castration-resistant human prostate cancers (CRPC), the majority of which exhibit AR signaling (r² = 0.37; P < 0.001; Supplementary Fig. S1A and S1B).

To further establish the role of AR in TMPRSS2 regulation in vivo, we quantitated TMPRSS2 transcripts in prostate epithelium in the context of pharmacologic manipulation of the AR axis. Men diagnosed with localized prostate adenocarcinoma were treated with the luteinizing hormone releasing hormone (LHHR) agonist leuprolide, or doses of estradiol sufficient to induce castrate serum levels of testosterone before radical prostatectomy. We isolated epithelial cells by laser-assisted microdissection and quantitated TMPRSS2 mRNAs by qRT-PCR. Compared with epithelium from untreated individuals, TMPRSS2 transcripts were significantly lower in men receiving leuprolide or estradiol (P < 0.01; Fig. 1G). In contrast, TMPRSS2 expression was not altered in tumor cells from men receiving cytotoxic chemotherapy (Supplementary Fig. S1C). We next confirmed the in vivo responsiveness of TMPRSS2 expression in the context of AR activity using the LuCaP35 xenograft model that regresses following castration (16). Over time, these xenografts develop a CRPC phenotype accompanied by reactivation of the AR signaling program. Using microdissection to directly compare equivalent cancer cell numbers in the xenografted tumors at different time points following castration, we found that TMPRSS2 is expressed highly in LuCaP35 tumor cells grown in eugonadal hosts, decreases at days 5 and 20 after castration, and increases with the emergence of CRPC (Supplementary Fig. S1D).

TMPPRSS2 Promotes Prostate Cancer Invasion and Metastasis

The extracellular protease function predicted by the TMPRSS2 coding sequence, coupled with findings of high TMPRSS2 levels in metastatic prostate cancers, suggested a functional role for TMPRSS2 in the pathogenesis of prostate cancer metastasis. To test this hypothesis, we evaluated the contribution of TMPRSS2 to the high frequency of metastasis observed in the transgenic autochthonous mouse model for prostate cancer (TRAMP; ref. 17). We crossed TRAMP mice to a strain with a targeted deletion of the Tmprss2 serine protease domain (18) and evaluated cohorts of Tmprss2−/−;TRAMP and Tmprss2+/−;TRAMP animals at 20 and 32 weeks of age. The frequency of primary prostate tumor development was not different between the two genotypes: 100% of the Tmprss2−/−;TRAMP and Tmprss2+/−;TRAMP animals developed prostate tumors grossly visible at necropsy (Fig. 2A). However,
Figure 1. Expression of TMPRSS2 in prostate carcinoma. A and C, qRT-PCR measurements of TMPRSS2, TMPRSS1, and ST14 mRNA from microdissected primary prostate carcinoma and metastasis from men with advanced CRPC. B, immunohistochemical localization of TMPRSS2 protein in benign prostate epithelium (white arrows) and prostate carcinoma (black arrows). TMPRSS2 in benign epithelium is oriented to the ductal lumen with little protein in contact with stromal constituents. In contrast, cancer cells expressing TMPRSS2 are in direct contact with stroma. D, TMPRSS2 protein in prostate cancer metastasis. Lymph node stroma and osteoid are denoted by an asterisk. The consistency of TMPRSS2 protein in multiple different metastases from 44 patients with advanced prostate cancer demonstrates that most metastatic foci express TMPRSS2 with a general concordance in multiple tumors from the same individual. Each data point represents an individual tumor focus and black (odd-numbered patients) and gray (even-numbered patients) data points alternate for clarity. E, TMPRSS2 protein staining intensity in ERG+ versus ERG− primary prostate cancers. F, representative example of TMPRSS2 protein expression in primary prostate cancers with or without ERG expression. G, expression of TMPRSS2 in human prostate epithelium is attenuated following treatment with androgen-suppressing therapeutics, estradiol, or the LHRH agonist leuprolide, compared with untreated controls.
Figure 2. TMPRSS2 influences prostate cancer growth and the development of metastasis. A, representative anatomic and histologic images of prostate glands from wild-type (WT; WT) and TRAMP mice with (Tmprss2\(^{+/-}\); TRAMP) and without (Tmprss2\(^{-/-}\); TRAMP) TMPRSS2 protease activity. Both TRAMP genotypes exhibited a spectrum of well-differentiated to poorly differentiated carcinomas. P, prostate gland; SV, seminal vesicle. Prostate glands are circled. B, weights of the genitourinary tracts (GU-SV) excised from TRAMP mice with (Tmprss2\(^{+/-}\); TRAMP) or without (Tmprss2\(^{-/-}\); TRAMP) TMPRSS2 activity. At 32 weeks of age, prostate tumors in Tmprss2\(^{-/-}\); TRAMP mice were substantially larger than those tumors excised from Tmprss2\(^{+/-}\); TRAMP animals (P = 0.01). C, the frequency of lymph node metastasis in Tmprss2\(^{-/-}\); TRAMP versus Tmprss2\(^{+/-}\); TRAMP genotypes was similar. The frequency of metastasis to solid organs in TRAMP mice with inactive TMPRSS2 was significantly reduced compared with TRAMP mice with wild-type TMPRSS2 (P = 0.02). D, basement membrane invasion assay demonstrating enhanced invasion of primary cells from Tmprss2\(^{WT}\); TRAMP tumors relative to benign epithelium or primary tumor cells deficient in TMPRSS2 activity (Tmprss2\(^{-/-}\); TRAMP). E, soft-agar colony formation assay demonstrating enhanced anchorage-independent growth of DU145 prostate cancer cells expressing wild-type active human TMPRSS2 (TMPRSS2\(^{WT}\)) versus a vector control or protease-dead TMPRSS2 mutant (TMPRSS2\(^{PM}\)). F, schematic of the metastasis assay: primary tumors developing in Tmprss2\(^{-/-}\); TRAMP or Tmprss2\(^{+/-}\); TRAMP were resected, cells dissociated, and injected into tail veins of recipient hosts. G, detection of SV40T antigen by PCR in blood (b), liver (l), or lung (lu) of mice at designated time points following tail-vein injections with primary prostate tumor cells from Tmprss2\(^{-/-}\); TRAMP or Tmprss2\(^{+/-}\); TRAMP mice. TCR, T-cell receptor. H, representative anatomic and histologic images of livers from mice receiving vascular injections of cells from Tmprss2\(^{-/-}\); TRAMP and Tmprss2\(^{+/-}\); TRAMP tumors.
primary tumor sizes and weights in the strains were significantly different; at 32 weeks, Tmprss2\(^{-/-}\) TRAMP tumors averaged 2.65 ± 0.65 g, whereas those arising in Tmprss2\(^{+/+}\) TRAMP animals were more than twice as large, averaging 6.39 ± 1.24 g \((P = 0.01)\) for difference; ref. Fig. 2B). Tumors in both strains were highly proliferative with Ki67 indices of 67% and 72% \((P = 0.6;\) ref. Fig. 2C). In contrast, the incidence of metastasis to distant organs was substantially lower in Tmprss2\(^{-/-}\) TRAMP animals \((n = 17)\) and Tmprss2\(^{+/+}\) TRAMP \((n = 16)\) strains exhibited a range of histologic patterns with a tendency toward more poorly differentiated tumors in the Tmprss2\(^{-/-}\) TRAMP genotype, although this was not statistically significant (Supplementary Fig. S2A).

At necropsy, we evaluated each animal for the presence of metastasis both grossly and by tissue histology. At the 32-week time point, tumor cell dissemination to regional lymph nodes was common in both Tmprss2\(^{+/+}\) (78%) and Tmprss2\(^{-/-}\) (83%) backgrounds \((P = 0.6;\) ref. Fig. 2C). In contrast, the incidence of metastasis to distant organs was substantially lower in the Tmprss2\(^{-/-}\) TRAMP tumors arising in the Tmprss2\(^{+/+}\) background. Of 18 Tmprss2\(^{+/+}\) TRAMP animals examined, 11 had gross metastasis to solid organs such as the liver and lung (61%), whereas only 2 of 30 Tmprss2\(^{-/-}\) TRAMP animals had macroscopically visible tumors (7%), with an additional 2 animals having microscopic foci in the liver \((P = 0.016;\) Fig. 2C). The AR and TMPRSS2 were expressed in primary tumors of both strains and in metastatic Tmprss2\(^{+/+}\) TRAMP tumor cells in liver and lung, although there were regions of metastasis with low-to-absent AR staining (Supplementary Fig. S2C–S2E).

Because of the germ line Tmprss2 loss-of-function mutation in the Tmprss2\(^{-/-}\) strain, the elimination of TMPRSS2 protease activity is not exclusive to prostate epithelium. To evaluate the possibility that TMPRSS2 influences tumor dissemination through nonprostatic cell types, we excised primary tumors, dispersed the tumor cells, ensured cellular viability, and measured growth in semisolid medium, and invasion through modified basement membrane by Transwell assays. Tmprss2\(^{-/-}\) TRAMP tumor cells were substantially more capable of invasion than either benign epithelium or cells from TRAMP tumors lacking TMPRSS2 protease \((P < 0.01;\) Fig. 2D). We next introduced shRNAs targeting Tmprss2 into LNCaP C4-2B cells and noted a significant reduction in cell proliferation and cell invasion compared with scrambled shRNA controls \((P < 0.001;\) Supplementary Fig. S3A and S3B). In addition, DU145 prostate cancer cells, a line that normally expresses no TMPRSS2, engineered to express wild-type TMPRSS2 were more capable of anchorage-independent growth than vector control DU145 cells or those expressing a protease-dead mutant form of TMPRSS2, TMPRSS2mol (Fig. 2E).

We next excised primary tumors from Tmprss2\(^{-/-}\) TRAMP and Tmprss2\(^{-/-}\) TRAMP strains, dissociated the tumors, and injected viable tumor cells into the tail vein of wild-type recipient mice (Fig. 2F). Using PCR to detect the presence of SV40T antigen as a surrogate for the presence of tumor cells, we assessed blood, liver, and lung over a time course of 28 days. SV40T antigen was readily detectable in the blood and tissues of mice injected with Tmprss2\(^{-/-}\) TRAMP tumor cells for up to 30 minutes, and in blood for up to 24 hours, after which the SV40T levels diminished markedly and were undetectable by day 14 (Fig. 2G). Nonviable tumor cells were rapidly cleared and were undetectable after 4 hours (Supplementary Fig. S4A). In contrast, SV40T DNA was readily measurable in the lung and liver 3 days after Tmprss2\(^{-/-}\) TRAMP tumor cell injection and remained detectable in these tissues until the time of necropsy at day 28, at which time gross metastases were evident. Primary tumors resected from 5 different Tmprss2\(^{-/-}\) TRAMP donor animals at age 32 weeks produced grossly visible liver or lung metastasis in 21 of 21 recipients, whereas tumor cells derived from Tmprss2\(^{-/-}\) TRAMP primary tumors failed to generate metastasis in any of 28 recipients \((P < 0.01;\) Table 1 and Fig. 2H).

### Table 1. Influence of Tmprss2 expression on the frequency of prostate cancer metastasis

<table>
<thead>
<tr>
<th>Donor age (wks)</th>
<th>Donor genotype</th>
<th>Recipients with metastases*</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Tmprss2(^{+/+}); TRAMP (n = 2)</td>
<td>0/3</td>
</tr>
<tr>
<td></td>
<td>Tmprss2(^{-/-}); TRAMP (n = 1)</td>
<td>0/3</td>
</tr>
<tr>
<td>20</td>
<td>Tmprss2(^{+/+}); TRAMP (n = 2)</td>
<td>9/9</td>
</tr>
<tr>
<td></td>
<td>Tmprss2(^{-/-}); TRAMP (n = 1)</td>
<td>0/3</td>
</tr>
<tr>
<td>32</td>
<td>Tmprss2(^{+/+}); TRAMP (n = 5)</td>
<td>21/21</td>
</tr>
<tr>
<td></td>
<td>Tmprss2(^{-/-}); TRAMP (n = 6)</td>
<td>0/28</td>
</tr>
</tbody>
</table>

ns: not significant.

*Number of recipient mice with metastasis/number of total recipient mice.

Comparison of the frequency of metastasis between donor genotypes.
We next evaluated the capability of TMPRSS2 to directly affect the survival and growth of prostate cancer cells in a distal site. The bone is a frequent location of prostate cancer metastasis in humans, although this predilection is poorly recapitulated in any spontaneous mouse model of prostate cancer for reasons that remain unclear. We injected cells directly harvested from 32-week Tmprss2−/−;TRAMP or Tmprss2−/−;TRAMP primary tumors into the tibia of recipient hosts. Mild radiographic abnormalities were noted in the bone engrafted with Tmprss2−/−;TRAMP cells, but tumor growth or bone destruction was not evident (Supplementary Fig. S4B). Radiographs of the bone engrafted with cells from Tmprss2−/−;TRAMP tumors demonstrated a marked expansile mass with mixed lytic and blastic features (Supplementary Fig. S4B). Histologic examination determined that 21 of 32 (66%) recipients of tumor cells derived from 6 different 32-week Tmprss2−/−;TRAMP donors had tumors, whereas none were identified in 29 recipients of tumor cells from 8 different Tmprss2−/−;TRAMP donors (P < 0.001). Two of 7 animals with Tmprss2−/−;TRAMP tibial grafts where distant organs were examined also had liver metastasis. No distant metastases were identified in mice grafted with cells from Tmprss2−/−;TRAMP tumors.

Identification of TMPRSS2 Substrate Specificity by Positional Scanning of Synthetic Combinatorial Peptide Libraries

To identify substrates of TMPRSS2 that could contribute to the metastatic phenotype, we took an approach designed to establish a hierarchy of likely target proteins based on biochemically defined cleavage specificity. To assess the primary (P1) and extended (P2–P4) TMPRSS2 cleavage sequence, we screened pools of synthetic peptides, each with a structure of Ac-P4-P3-P2-P1-ACC (7-amino-4-carbamoylmethylcoumarin; refs. 20, 21). We tested TMPRSS2 against 160,000 distinct peptides for proteolytic activity in vitro. At the P1 position, TMPRSS2 strongly preferred substrates with an arginine rather than a lysine (Fig. 3A). The P2–P4 specificity of TMPRSS2 is distinct from the optimal cleavage specificities defined for other extracellular serine proteases, including hepsin, MT-SP1/matriptase, thrombin, plasmin, tryptases β1 and βII, prostasin, and KLK4 (Supplementary Fig. S5), but TMPRSS2 also exhibits a degree of overlap with hepsin and MTSP1 substrates (22–25). We next created a database of human sequences that contain a trypsin-like fold as extracted from Pfam and MEROPS databases. On the basis of the information obtained from the TMPRSS2 Positional Scanning of Synthetic Combinatorial peptide Libraries (PS-SCL) peptide profiling, we identified serine protease fold–like proteins that had (i) activation domains comprising a known or predicted P4–P1 sequence, (ii) P1 position comprised of arginine, and (iii) a P1′ position comprising a hydrophobic amino acid (isoleucine or valine) to bind to the large, hydrophobic S1 pocket of TMPRSS2 (Supplementary Fig. S6A–SAC).

Results of TMPRSS2 substrate screening identified the activation sequences PQFR in the zymogen precursors of tissue plasminogen activator (PLAT), and IQSR in human glandular kallikrein 2 (hK2). Of interest, both PLAT and hK2 participate in protease cascades culminating in the anticoagulation of blood or seminal fluid, respectively (26, 27). We confirmed that TMPRSS2 proteolyzed pro-hK2 and exhibited no activity toward MMP2 and MMP9, proteins without predicted TMPRSS2 cleavage sites (Supplementary Fig. S7A–S7D). hK2 is produced by benign prostate epithelial cells and is secreted into the glandular lumen, where it is known to activate prostate-specific antigen (PSA), a protease that in turn lyses the procoagulant seminogelin seminal fluid proteins. These results indicate that TMPRSS2 participates in proteolytic cascades of relevance for the normal physiologic function of the prostate.

TMPRSS2 Activates Hepatocyte Growth Factor, Promotes Signaling through c-MET, and Engages a Gene-Expression Program Contributing to Metastasis

Results of TMPRSS2 substrate screening identified the peptide KQR, a sequence identical to the activation sequence of the single-chain precursor form of HGF. HGF has structural similarity to serine proteases, and functions as the ligand of the c-MET receptor tyrosine kinase (28). Several studies have shown that HGF and c-MET comprise a signaling pathway of relevance for prostate cancer invasion and metastasis (29, 30). Cleavage of the single-chain HGF precursor by known activators such as HGFAC and matriptase produces a functional α/β-heterodimeric HGF capable of engaging the c-MET receptor (31). To test whether TMPRSS2 could activate HGF, we evaluated its proteolytic activity toward a preparation of precursor sc-HGF. Exposure to active TMPRSS2 resulted in the loss of detectable pro-scHGF (Fig. 3B), an observation not recapitulated following incubation with a protease-inactive TMPRSS2 mutant or vehicle control. We next confirmed that the TMPRSS2-processed HGF, HGF TMPRSS2, activates the c-MET receptor. We exposed DU145 cells, known to express c-MET, with pro-HGF preincubated with matriptase, a known activator of HGF. MET activation was determined by demonstrating receptor phosphorylation (Fig. 3C). Exposure of these cells to pro-HGF alone did not result in detectable MET phosphorylation. However, pro-HGF activated by incubation with TMPRSS2 resulted in MET phosphorylation. The inclusion of anti-HGF–neutralizing antibody eliminated MET phosphorylation. The addition of anti-HGF–neutralizing antibody to conditioned medium from prostate fibroblasts also significantly increased the invasion of DU145 cells, an effect that was not observed with a TMPRSS2 protease mutant, or the addition of HGF–neutralizing antibody or the c-MET inhibitor SU11274 (Fig. 4B). LNCaP and C4-2B cells that natively express TMPRSS2, and PC3 and DU145 cells engineered to express TMPRSS2 exhibited enhanced invasion when exposed to pro-HGF (P < 0.01; Fig. 4C–E; Supplementary Fig. S7E).

The unanticipated finding that primary tumors developing in Tmprss2−/−;TRAMP mice were substantially larger than those arising in Tmprss2−/−;TRAMP mice, yet possessed attenuated metastatic capabilities, prompted further studies to evaluate the role of HGF in this process. When exposed to HGF, DU145 cells increased rates of proliferation...
Figure 3. Identification of TMPRSS2 protease substrates. A, results of PS-SCL. The amino acid cleavage preferences are P1 (R); P2 (T,F,W,A,V); P3 (E,M,Q); P4 (G,I,M); n designates the amino acid norleucine. B, pro-HGF is a substrate for TMPRSS2. The arrow denotes the single-chain (pro-)HGF and is not visualized following incubation with active TMPRSS2. The inactive TMPRSS2 protease-dead mutant (TMPRSS2 PM ) is incapable of catalyzing HGF proteolysis. TMPRSS2 does not degrade the BSA carrier protein (dominant bands). Western blot analysis using a polyclonal anti-HGF antibody that recognizes multiple epitopes in the α and β chains of HGF demonstrates the loss of single-chain (pro-)HGF following incubation with active TMPRSS2 (lane 2), but not protease-dead TMPRSS2 (lane 3). C, pro-HGF proteolyzed by TMPRSS2 activates c-MET as determined by immunodetection of phospho-rylated c-MET (p-c-MET) in DU145 prostate cancer cells. Control reactions with matriptase also demonstrate c-MET activation. Pro-HGF alone and the addition of anti-HGF–neutralizing antibody abolishes c-MET phosphorylation.

(P < 0.01; Fig. 4F). However, HGF suppressed the proliferation of TC2 cells, a line derived from a TRAMP tumor (P < 0.03; Fig. 4G), while still promoting invasion (Fig. 4H). Similarly, the proliferation of nontumorigenic BPH1 cells was suppressed by HGF exposure (Fig. 4G). Consistent with these observations, TC2 cells exposed to HGF upregulated the expression of cell-cycle inhibitors p21 and p27 with concomitant decreases in proliferating nuclear antigen (PCNA), whereas PCNA expression increased in DU145 cells (Fig. 4I and J). These studies demonstrate that HGF signaling can simultaneously suppress cell proliferation while enhancing invasive phenotypes.

As HGF signaling is known to promote a prometastatic epithelial-to-mesenchymal transition (EMT; refs. 32, 33), we examined the expression of genes contributing to such a phenotype. We first confirmed that TMPRSS2 and c-MET were expressed in primary and metastatic Tmprss2+/+;TRAMP tumors (Fig. 5A). We next microdissected benign prostate epithelium from wild-type animals and neoplastic prostate epithelium from age-matched Tmprss2−/−;TRAMP and Tmprss2−/−;TRAMP strains. Microarray-based transcript profiling determined that genes associated with EMT are expressed at substantially higher levels in Tmprss2+/+;TRAMP tumor cells relative to Tmprss2−/−;TRAMP cells or benign epithelium (Fig. 5B and C). We confirmed increases in the gene encoding the mesenchymal marker vimentin (2.1-fold) and EMT-associated transcripts encoding TWIST1 (5.7-fold) and TWIST2 (1.7-fold) by qRT-PCR (Fig. 5D). HGF signaling has been shown to promote invasive phenotypes through transcriptional regulation of the genes encoding CXCL12/CXCR4 chemokine components (34). Tumors excised from the highly metastatic TRAMP strain expressed 15-fold higher levels of Cxcl12 (Fig. 5D), whereas Tmprss2−/−; TRAMP cells expressed Cxcl12 at levels equivalent to benign epithelium. Immunohistochemical staining confirmed that Tmprss2+/+;TRAMP tumor cells express high levels of the EMT-associated proteins vimentin and N-cadherin, and reductions of both were apparent in tumors arising in the absence of TMPRSS2 (Fig. 5E). These findings indicate that TMPRSS2 influences an EMT phenotype associated with enhanced cellular motility, invasion, and metastasis (Fig. 5F).
Figure 4. TMPRSS2-activated HGF consistently promotes invasion but differentially enhances or suppresses proliferation. **A**, exposure of DU145 prostate cancer cells to pro-HGF activated by either TMPRSS2 or matriptase increases cellular invasion. **B**, exposure of DU145 prostate cancer cells to prostate fibroblast-conditioned medium and TMPRSS2 increases cellular invasion, which is not observed with an inactive TMPRSS2 protease mutant (TMPRSS2 PM) and abolished with the addition of anti-HGF–neutralizing antibody or the c-MET inhibitor SU11274. The proinvasive phenotype associated with TMPRSS2 expression in LNCaP (**C**), PC3 (**D**), and DU145 (**E**) cells is promoted by exogenous paracrine-acting HGF. SF, serum-free medium. **F** and **G**, TMPRSS2-activated HGF enhances the proliferation of DU145 cells and suppresses the proliferation of BPH1 and TRAMP C2 cells (TC2). Cell numbers were determined at 96 hours and represent a mean of three replicates (*, \( P < 0.01 \)). **H**, invasion of TRAMP C2 cells is promoted by TMPRSS2-activated HGF and attenuated with anti-HGF–neutralizing antibody (*, \( P < 0.01 \)). **I** and **J**, differential effects of activated HGF on cell-cycle regulators p21 and p27 in TC2 (**I**) and DU145 (**J**) cells.
Figure 5. TMPRSS2 associates with a gene-expression program involved in EMT. A, Ar and Met transcript levels in primary and metastatic TRAMP tumors determined by qRT-PCR. B, transcript profiling of mRNAs from microdissected prostate epithelium. Genes associated with EMT are elevated in Tmprss2^WT^; TRAMP tumors (yellow) and decreased in Tmprss2^−/−^; TRAMP tumors (blue). C, gene set enrichment analysis (GSEA) confirms a significant enrichment in EMT-associated genes in Tmprss2^WT^; TRAMP tumors (P < 0.001). D, qRT-PCR quantitation of gene expression from benign and neoplastic epithelium microdissected from TRAMP mouse strains with and without TMPRSS2 activity. E, immunohistochemical staining of TRAMP tumors for EMT-associated proteins vimentin and N-cadherin. F, schematic view of the proteolytic cascades influenced by TMPRSS2 in the context of normal physiology in benign epithelium and in neoplasia where substrates normally confined to the stroma are available for interactions with the TMPRSS2 protease. SC, secretory epithelial cell; BC, basal epithelial cell; BM, basement membrane; CC, cancerous epithelial cell.
Chemical Library Screens Identify Bromhexine Hydrochloride as a Bioavailable TMPRSS2 Inhibitor That Suppresses Metastasis

To identify inhibitors of TMPRSS2 that may be used directly in clinical studies or as lead compounds to develop targeted drugs, we screened several chemical libraries with active TMPRSS2 protease, the chromogenic TMPRSS2 peptide substrate Boc–Gln–Ala–Arg–MCA, and compound concentrations of 5 μM/L. We have used a similar approach to identify inhibitors of the hepsin protease (35). As a measure of reproducibility, the Z′ score for this assay was 0.78. The chemical libraries included 1,248 FDA-approved compounds, a Chembridge library of 13,920 compounds, and a Chem-Div library of 54,720 compounds. These screens led to the identification of five chemicals that inhibit TMPRSS2 protease activity, of which one, bromhexine hydrochloride (BHH), is an FDA-approved ingredient in mucolytic cough suppressants (S6A) and four are known only by their chemical identification numbers or Chemical Abstracts Service (CAS) identifiers (Supplementary Fig. S8A).

The identified inhibitors—BHH, 0591-5329, 4401-0077, 4554-5138, and 8008-1235—were used in titration assays to determine the IC50 values toward TMPRSS2, which ranged from 0.75 μM/L for BHH to 2.68 μM/L for 8008-1235. Each compound exhibited strong specificity toward TMPRSS2 relative to the related hepsin and matriptase proteases (Fig. 6B). BHH IC50 values for hepsin and matriptase were 35 and 58 μM/L, respectively, and exceeded 100 μM/L for trypsin and thrombin (Supplementary Fig. S8B and S8C).

We next confirmed that the identified inhibitors were able to block the ability of TMPRSS2 to activate pro-PLAT in vitro. Assays consisted of preincubation of recombinant active TMPRSS2 with each compound, followed by a 2-hour incubation with recombinant pro-PLAT. At the IC50 concentrations, each compound substantially suppressed TMPRSS2-mediated proteolysis of this putative physiologic substrate (Fig. 6C).

Of the five TMPRSS2 inhibitors identified in the screens, only BHH has been available in sufficient quantities to allow for further in vitro and in vivo studies. We assessed the toxicity and effects of BHH on cellular phenotypes of proliferation and invasion using in vitro cell-based assays. No significant toxicity was observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to BHH concentrations ranging from 0 to 250 μM/L (Fig. 6D and Supplementary Fig. S9A and S9B). Because we have shown that TMPRSS2 activates HGF and is involved in promoting cellular invasion and migration, we tested BHH for effectiveness in preventing invasion in a Matrigel-based in vitro culture invasion assay. DU145 and PC3 cells engineered to express TMPRSS2 were substantially more invasive than vector control cells either with standard culture conditions or with the addition of HGF (P < 0.01). BHH treatment significantly reduced the invasion and migration phenotypes promoted by HGF in both DU145TMPRSS2 and PC3TMPRSS2 cells (P < 0.01; Fig. 6E and F). BHH also significantly attenuated HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2 (P < 0.01; Supplementary Fig. S9C and S9D).

Given that BHH is an FDA-approved compound that has been used widely with no substantial adverse effects, we undertook a series of in vivo studies. Wild-type C57BL/6 and TRAMP mice were treated three times per week by intraperitoneal injection of 30 mg/kg of BHH, a dose equivalent to approximately 2% of the acute LD50 dose in the published rodent toxicity studies. Treatments began at 15 weeks, an age at which the TRAMP mice are expected to have prostatic intraepithelial neoplasia (PIN), and continued for approximately 20 weeks until an age when the majority develop metastatic disease. In wild-type mice, no systemic toxicities were observed, and there were no anatomic or histologic alterations in the prostate glands when compared with mice treated with DMSO vehicle. The prostate weights were not different (0.51 g vs. 0.56 g; P = 0.55). As expected, the prostate of the vehicle-treated TRAMP mice were significantly larger than those of vehicle-treated wild-type C57BL/6 mice (1.6 g vs. 0.56 g; P < 0.001), and the histology of mice with a TRAMP genotype comprised a range of hyperplasia to invasive carcinomas. Notably, the prostate glands of the TRAMP mice treated with BHH were generally substantially larger than those of the vehicle-treated TRAMP mice (5.2 ± 0.6 g vs. 1.6 ± 0.3 g; P < 0.01; Fig. 6G and H). Furthermore, BHH treatment significantly reduced the incidence of distant metastasis to lung and liver sites from 55% in vehicle-treated animals to 20% with BHH (P = 0.04; Fig. 6I). Collectively, these findings phenocopy the observations made in the context of genetic Tmprss2 manipulation where Tmprss2−/−;TRAMP mice had larger primary tumors but reduced metastasis compared with Tmprss2−/−;TRAMP animals.

To further assess the effects of BHH on metastasis, we injected tumor cells freshly harvested from primary TRAMP tumors into the tail veins of recipient mice. BHH (30 mg/kg) or 1% DMSO (vehicle control) was administered 1 day before tumor cell injection, on the day of tumor injection, and then three times per week for 8 weeks. At necropsy, 87% and 93% of vehicle-treated mice were found to have histologically confirmed lung or liver metastasis, respectively. In contrast, mice treated with BHH had substantially fewer lung (33% vs. 87%; P < 0.01) and liver (27% vs. 93%; P < 0.01) tumors (Fig. 6I and J).

DISCUSSION

The vast majority of deaths attributable to prostate cancer result from metastasis. Although strong evidence supports a central role for AR-directed signaling in promoting the survival and proliferation of prostate cancers, contributions of the AR program to the metastatic process have not been established. Here, we demonstrate that TMPRSS2, a serine protease regulated through AR transactivation and expressed at consistently high levels in prostate cancer metastasis, is a potent activator of HGF. Through interactions with the c-MET receptor tyrosine kinase, HGF orchestrates well-described developmental programs and contributes to pathologic processes, including carcinogenesis (36). Of particular relevance to the present study, c-MET-regulated programs can endow neoplastic epithelial cells with migratory and invasive capabilities and facilitate the acquisition of phenotypes normally associated with mesenchymal lineages. Abrerrant c-MET signaling has been shown to occur through mechanisms that include activating point mutations, genomic amplification, and the
Figure 6. TMPRSS2 chemical inhibitors suppress prostate tumor growth and metastasis in vivo. A, chemical structure of the identified TMPRSS2 inhibitor BHH. B, BHH exhibits substantially greater inhibitory activity toward TMPRSS2 relative to hepsin or matriptase. Optimal peptide substrates were used for each enzyme and substrate concentrations were determined after 30 minutes. C, suppression of TMPRSS2-induced cleavage of the TMPRSS2 substrate pro-PLAT by the chemical TMPRSS2 inhibitors identified through screening chemical libraries. T2 is active TMPRSS2. D, BHH exposure does not induce cell death or substantially suppress the growth of DU145 cells. BHH suppresses the serum- and HGF-mediated invasion of (E) DU145 and (F) PC3 cells expressing TMPRSS2. G, in vivo treatment with BHH increases the size of primary TRAMP tumors compared with TRAMP mice treated with DMSO vehicle. Treatment was initiated at age 15 weeks and tumor weights were determined after 20 weeks of treatment. H, TRAMP mice treated with BHH have substantially fewer spontaneous metastases to lung or liver. I, BHH treatment substantially reduced the frequency of distant metastasis following tail-vein injections of tumor cells harvested from primary TRAMP tumors. J, representative histology of murine liver 8 weeks following the intravenous injection of TRAMP tumor cells showing liver metastasis in mice treated with DMSO vehicle and normal liver histology without metastasis in BHH-treated mice.

<table>
<thead>
<tr>
<th>DMSO</th>
<th>BHH</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumor (g)</td>
<td>1.6 ± 0.3</td>
<td>5.2 ± 0.6</td>
</tr>
<tr>
<td>LN metastasis (%)</td>
<td>18/20 (90)</td>
<td>13/20 (65)</td>
</tr>
<tr>
<td>Organ metastasis (%)</td>
<td>11/20 (55)</td>
<td>4/20 (20)</td>
</tr>
</tbody>
</table>
autocrine production of HGF by tumor cells (37). c-MET signaling is also promoted through paracrine interactions with HGF generated by constituents of the tumor microenvironment such as fibroblasts, endothelial cells, and leukocytes (38). In this situation, pro-HGF is converted to mature HGF by cell-surface proteolysis (36). The sequestration of HGF by constituents of extracellular matrix, coupled with the limited capability of active HGF to diffuse through extracellular domains, strongly favors c-MET signaling in cell types capable of establishing intimate spatial relationships juxtaposing cell surface–localized proteases and receptor-bound pro-HGF. Such a mechanism has been shown to occur in squamous cell carcinoma, in which the TMPRSS2 family member matrkapine induces tumorogenesis through proteolytic conversion of pro-HGF, consequent activation of c-MET signaling, and engagement of the PI3K–AKT–mTOR pathway (39).

Several lines of clinical evidence support a central role for signaling networks operating to promote a metastatic cascade in prostate cancer that involve AR, TMPRSS2, HGF, and c-MET interactions. Both the native prostate stroma, and constituents of bone, particularly osteoblasts, are known to generate high levels of HGF (40, 41). Striking regressions of prostate bone metastasis have been documented in human clinical trials of the c-MET inhibitor cabozantinib (42). Engagement of c-MET signaling induces a proinvasive EMT accompanied by a switch from E-cadherin to N-cadherin expression. N-cadherin is highly expressed by a subset of human prostate cancers with invasive and metastatic capabilities (43). We found that loss of TMPRSS2 expression in TRAMP prostate tumors attenuated their metastatic capabilities and was associated with marked reductions of N-cadherin protein. A plausible model linking these events involves the induction of TMPRSS2 expression by AR-regulated transcription with consequent TMPRSS2 proteolysis of paracrine pro-HGF. The resulting engagement of c-MET signaling induces an invasive phenotype involving the acquisition of mesenchymal characteristics marked by the switch to N-cadherin production. Although the TRAMP model often develops neuroendocrine and poorly differentiated tumors accompanied by diminished AR activity with disease progression, early-stage tumors exhibit robust AR expression and respond to androgen deprivation with tumor regression. For relevance of the present observations, metastatic human prostate cancers can exist as mixed tumors with both AR+ and AR− cells and also as hybrid tumors with concurrent expression of the AR and neuroendocrine markers within the same tumor cells (44). In this context, AR+TMPRSS2+ cells may activate HGF to exert paracrine effects on nearby cells that lack AR or TMPRSS2 activity, but that express c-MET.

Although loss of TMPRSS2 protease activity substantially attenuated metastasis, the localized tumors that arose in the absence of TMPRSS2 were unexpectedly of substantially greater size. This observation divorces primary tumor growth from metastatic behavior, and although counterintuitive, the findings are concordant with emerging views of metastasis (45, 46). There is precedent for the discordance between primary tumor size and metastatic capabilities involving prooncogenic signaling (47). Our results, involving differential microenvironment HGF states based on TMPRSS2-mediated activation, are also consistent with well-documented dichotomous effects of HGF, whereby proliferative versus growth-suppressing effects occur depending on cell context (36). HGF has been shown to restrain the proliferation of benign prostate epithelial cells and enhance growth rates of malignant cells, while inducing the migration of both cell types (30). HGF-mediated growth-inhibitory and growth-stimulatory responses have also been observed in cells derived from breast, ovarian, and other neoplasms (36). The downstream molecular interactions and signaling networks dictating the divergent reactions to HGF–c-MET signaling remain to be clarified.

A reduction in the frequency of metastases was also achieved by pharmacologic inactivation of TMPRSS2 with bromhexine, an FDA-approved drug. This result not only further validates TMPRSS2 as a drug target but also offers an opportunity for clinical studies. The magnitude of the reduction in metastases with bromhexine was lower than observed by genetic ablation of Tmprs2, which may reflect incomplete pharmacologic blockade of protease activity with the treatment schedule we used. As bromhexine is orally bioavailable, more frequent oral dosing may allow more complete and protracted inactivation of the enzyme in eventual clinical trials.

In summary, this study supports a causal role for TMPRSS2 in modulating the metastatic behavior of prostate cancer. The elevated levels of TMPRSS2 expression in high-grade localized carcinomas, and in disseminated tumor cells, coupled with regulatory controls exerted through AR activity, suggest that this protease could represent a key effector of androgen-driven prostate cancer progression. These results link the AR program to the metastatic phenotype through mechanisms that depend on interactions with constituents of the local and distant tumor microenvironment, and suggest that therapeutic approaches directed toward inhibiting TMPRSS2 may reduce the incidence or progression of metastasis in patients with prostate cancer.

METHODS

Mouse Strains and Tissue Analyses

All mouse studies were performed under IACUC-approved protocols. The generation and characterization of Tmprss2−/− and the TRAMP mice have previously been described (17, 18, 48). Hematoxylin and eosin (H&E) staining was performed on 5-μm sections from various organs and reviewed by two pathologists (Funda Vakar-Lopez and L.D. True) without knowledge of the genotype of the animals and evaluated in accordance with previously described TRAMP tumor pathology (19, 48). Additional details are provided in Supplementary Methods.

Gene-Expression Assays

Laser-assisted microdissection was used to capture prostate epithelia from the ventral and anterior prostatic lobes, as previously described (49). Microarray hybridization and qRT-PCR were used to quantify mRNA abundance, as detailed in Supplementary Methods. Microarray data are accessible in the Gene Expression Omnibus (GEO) using accession number GSE58822. Primer sequences and PCR conditions for the various genes analyzed are provided in Supplementary Methods.

Cell Culture and Phenotypic Assays

Cell lines used in these studies were used within six passages of original receipt or authenticated by comparing transcript profiles with those generated from original stocks. Additional details are...
provided in Supplementary Methods. The TMPRSS2 coding sequence was cloned into the pcDNA1 TOP0 vector following the manufacturer’s protocol (Invitrogen), transfected into prostate cancer cells, and stable cell lines generated under antibiotic selection as detailed in Supplementary Procedures. The effect of TMPRSS2 on prostate cancer cell proliferation was determined by measuring the growth rates of individually selected TMPRSS2-expressing cell line clones in triplicate in 6-well tissue culture plates. Cells were trypsinized, stained with Trypan blue, and counted every 2 days for 8 days. The number of metabolically active cells was measured every day for 8 days using the CellTiter 96 Cell Proliferation Assay from Promega. Cell invasion assays were performed using the QCM 96-Well Invasion Assay from Chemicon. Anchorage-independent growth differences were assayed as previously described (50).

Metastasis and Xenograft Assays

Primary prostate tumors were removed from Tmprss2 exon 18; TRAMP or Tmprss2loxP:TRAMP mice at 28 to 32 weeks of age and transferred into phenol red-free RPMI-1640 with 10% FBS and antibiotics. Part of each tumor was fixed or frozen for histologic analysis. Tumor tissue was minced with scalpels and passed through a 100-μm cell strainer (BD Falcon). Live cell number was estimated by Trypan blue exclusion using a hemocytometer. Approximately 5 × 10^7 live cells were injected into the tail veins of 6- to 8-week-old male ICR SCID mice (Taconic). SCID recipients were euthanized 8 weeks after injection. Intratibial injection of primary tumor cells was performed essentially as previously described (51). Mice were euthanized 8 weeks after injection. Radiographic images were obtained using a Faxitron with Kodak miniR2000 film.

TMPRSS2 Substrate Identification

The methods for PS-SCL were performed as described previously (20) and specific details are provided in Supplementary Methods. To identify preferred protein substrates for TMPRSS2, we used the information obtained from the PS-SCL peptide profiling and the testing of individual peptide substrates to create a database of human sequences that contain a trypsin-like fold as extracted from Pfam and MEROPS databases. Candidate proteins were clustered and ranked based on matches with the preferred amino acids at the P1–P4 positions. We then tested the ability of TMPRSS2 to cleave selected candidate substrates from each cluster, such as the HGF precursor, PLAT, and KLK2, using standard in vitro digests, PAGE, and Western blotting, as described in Supplementary Methods.

In Vivo Assays of Bromhexine

Primary prostate tumors were removed from TRAMP mice and transferred into phenol red-free RPMI-1640 with 10% FBS and antibiotics. The tumors were minced with scalpels and passed three times through a 100-μm cell strainer (BD Falcon). Dissociated live cells were counted using Trypan blue exclusion and a hemocytometer. Six- to 8-week-old ICR SCID mice were anesthetized with isoflurane and placed in a stereotactic frame. Approximately 5 × 10^6 live cells were injected into the tail veins of mice. Mice also received the drug treatment on the day of tumor injection and then every other day for 8 weeks, at which point the animals were euthanized necropsied, and examined for tumor growth, paying specific attention to their livers, lungs, and kidneys.

Disclosure of Potential Conflicts of Interest

E. Mostaghel has received honoraria from the speakers’ bureau of Janssen. No potential conflicts of interest were disclosed by the other authors.

REFERENCES


NOVEMBER 2014 CANCER DISCOVERY | 1323

Authors’ Contributions


Acknowledgments

The authors thank Alex Moreno for administrative assistance, Ruth Ettioni and Roman Gulati for statistical input, Valera Vasioukhin for helpfull discussions, Funda Vakar-Lopez and Sue Knoblagh for pathology support, and the Tissue Acquisition Necropsy Team at the University of Washington (Robert Vessella, Celestia Higano, Evon Yu, William Ellis, Martine Roudier, Beatrice Knudsen, Jennifer Noteboom, and Paul Lange). The authors also thank Norm Greenberg for providing the TRAMP mouse strain. The authors are very grateful to the prostate cancer patients participating in these studies.

Grant Support

This work was supported by the Prostate Cancer Foundation (to E. Mostaghel and P.S. Nelson); NIH grants P01CA88595 (to J.M. Lucas, C. Heinlein, T. Kim, S.A. Hernandez, M.S. Malik, L.D. True, C. Morrissey, E. Corey, N. Clegg, I. Coleman, and P.S. Nelson), R01CA165573 (to I. Coleman and P.S. Nelson), and U01CA164188 (to P.S. Nelson); and the Pacific Northwest Prostate Cancer SPORE P50CA97186 (to L.D. True, C. Morrissey, B. Montgomery, E. Mostaghel, and P.S. Nelson).

Received December 19, 2013; revised August 7, 2014; accepted August 8, 2014; published OnlineFirst August 13, 2014.
The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis

Jared M. Lucas, Cynthia Heinlein, Tom Kim, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-13-1010

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2014/08/15/2159-8290.CD-13-1010.DC1

Cited articles
This article cites 51 articles, 19 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/4/11/1310.full#ref-list-1

Citing articles
This article has been cited by 40 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/4/11/1310.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerdiscovery.aacrjournals.org/content/4/11/1310.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.